Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the children's oncology group

Ian F. Pollack, Ronald L. Hamilton, Robert W. Sobol, Marina N. Nikiforova, Yuri E. Nikiforov, Maureen A. Lyons-Weiler, William A. LaFramboise, Peter C. Burger, Daniel J. Brat, Marc K. Rosenblum, Floyd H. Gilles, Allan J. Yates, Tianni Zhou, Kenneth J Cohen, Jonathan L. Finlay, Regina I. Jakacki

Research output: Contribution to journalArticle

Abstract

Background: Alkylating agents are commonly used in the treatment of childhood malignant gliomas. Overexpression of O6-methylguanine-DNA methyltransferase (MGMT) constitutes an important mechanism for resistance to such agents, and MGMT status has been associated with outcome in several recent trials. Deficiency in mismatch repair (MMR) function has been implicated in preclinical studies as an additional potential mechanism of resistance to methylating agents, such as temozolomide, independent of tumor MGMT status. However, the frequency of this abnormality as a clinical resistance mechanism in childhood malignant gliomas has not been well characterized. Methods: To address this issue, we examined the frequency of microsatellite instability (MSI), a marker of defective MMR, in a series of 68 tumors, derived from newly diagnosed patients treated on the Children's Cancer Group 945 study, and the Children's Oncology Group ACNS0126 and 0423 studies. MSI was assessed using a panel of six microsatellite markers, including BAT-25, BAT-26, CAT-25, D2S123, D5S346, and D17S250. MGMT immunoreactivity was assessed in parallel to allow comparison of the relative incidence of MGMT overexpression and MSI. Results: Only three tumors had high-level MSI involving three or more markers; the remainder had no MSI at any of the loci examined. These children did not have unusual features in terms of their outcome. In contrast to the infrequency of MSI, 25 tumors (37%) exhibited MGMT overexpression as assessed by immunohistochemistry. None of the tumors with MSI exhibited overexpression of MGMT. Conclusion: MMR deficiency is an infrequent contributor to initial alkylator resistance in children with malignant gliomas.

Original languageEnglish (US)
Pages (from-to)1066-1071
Number of pages6
JournalPediatric Blood and Cancer
Volume55
Issue number6
DOIs
StatePublished - Dec 2010

Fingerprint

Microsatellite Instability
Alkylating Agents
Methyltransferases
Glioma
Pediatrics
DNA
Neoplasms
temozolomide
DNA Mismatch Repair
Turcot syndrome
Microsatellite Repeats
Immunohistochemistry
Incidence

Keywords

  • Anaplastic glioma
  • Childhood
  • Glioblastoma
  • MGMT
  • Microsatellite instability
  • Mismatch repair
  • Treatment resistance

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Pollack, I. F., Hamilton, R. L., Sobol, R. W., Nikiforova, M. N., Nikiforov, Y. E., Lyons-Weiler, M. A., ... Jakacki, R. I. (2010). Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the children's oncology group. Pediatric Blood and Cancer, 55(6), 1066-1071. https://doi.org/10.1002/pbc.22634

Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas : A report from the children's oncology group. / Pollack, Ian F.; Hamilton, Ronald L.; Sobol, Robert W.; Nikiforova, Marina N.; Nikiforov, Yuri E.; Lyons-Weiler, Maureen A.; LaFramboise, William A.; Burger, Peter C.; Brat, Daniel J.; Rosenblum, Marc K.; Gilles, Floyd H.; Yates, Allan J.; Zhou, Tianni; Cohen, Kenneth J; Finlay, Jonathan L.; Jakacki, Regina I.

In: Pediatric Blood and Cancer, Vol. 55, No. 6, 12.2010, p. 1066-1071.

Research output: Contribution to journalArticle

Pollack, IF, Hamilton, RL, Sobol, RW, Nikiforova, MN, Nikiforov, YE, Lyons-Weiler, MA, LaFramboise, WA, Burger, PC, Brat, DJ, Rosenblum, MK, Gilles, FH, Yates, AJ, Zhou, T, Cohen, KJ, Finlay, JL & Jakacki, RI 2010, 'Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the children's oncology group', Pediatric Blood and Cancer, vol. 55, no. 6, pp. 1066-1071. https://doi.org/10.1002/pbc.22634
Pollack, Ian F. ; Hamilton, Ronald L. ; Sobol, Robert W. ; Nikiforova, Marina N. ; Nikiforov, Yuri E. ; Lyons-Weiler, Maureen A. ; LaFramboise, William A. ; Burger, Peter C. ; Brat, Daniel J. ; Rosenblum, Marc K. ; Gilles, Floyd H. ; Yates, Allan J. ; Zhou, Tianni ; Cohen, Kenneth J ; Finlay, Jonathan L. ; Jakacki, Regina I. / Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas : A report from the children's oncology group. In: Pediatric Blood and Cancer. 2010 ; Vol. 55, No. 6. pp. 1066-1071.
@article{955bee4e46664c5c805cd2d4ea93e089,
title = "Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the children's oncology group",
abstract = "Background: Alkylating agents are commonly used in the treatment of childhood malignant gliomas. Overexpression of O6-methylguanine-DNA methyltransferase (MGMT) constitutes an important mechanism for resistance to such agents, and MGMT status has been associated with outcome in several recent trials. Deficiency in mismatch repair (MMR) function has been implicated in preclinical studies as an additional potential mechanism of resistance to methylating agents, such as temozolomide, independent of tumor MGMT status. However, the frequency of this abnormality as a clinical resistance mechanism in childhood malignant gliomas has not been well characterized. Methods: To address this issue, we examined the frequency of microsatellite instability (MSI), a marker of defective MMR, in a series of 68 tumors, derived from newly diagnosed patients treated on the Children's Cancer Group 945 study, and the Children's Oncology Group ACNS0126 and 0423 studies. MSI was assessed using a panel of six microsatellite markers, including BAT-25, BAT-26, CAT-25, D2S123, D5S346, and D17S250. MGMT immunoreactivity was assessed in parallel to allow comparison of the relative incidence of MGMT overexpression and MSI. Results: Only three tumors had high-level MSI involving three or more markers; the remainder had no MSI at any of the loci examined. These children did not have unusual features in terms of their outcome. In contrast to the infrequency of MSI, 25 tumors (37{\%}) exhibited MGMT overexpression as assessed by immunohistochemistry. None of the tumors with MSI exhibited overexpression of MGMT. Conclusion: MMR deficiency is an infrequent contributor to initial alkylator resistance in children with malignant gliomas.",
keywords = "Anaplastic glioma, Childhood, Glioblastoma, MGMT, Microsatellite instability, Mismatch repair, Treatment resistance",
author = "Pollack, {Ian F.} and Hamilton, {Ronald L.} and Sobol, {Robert W.} and Nikiforova, {Marina N.} and Nikiforov, {Yuri E.} and Lyons-Weiler, {Maureen A.} and LaFramboise, {William A.} and Burger, {Peter C.} and Brat, {Daniel J.} and Rosenblum, {Marc K.} and Gilles, {Floyd H.} and Yates, {Allan J.} and Tianni Zhou and Cohen, {Kenneth J} and Finlay, {Jonathan L.} and Jakacki, {Regina I.}",
year = "2010",
month = "12",
doi = "10.1002/pbc.22634",
language = "English (US)",
volume = "55",
pages = "1066--1071",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas

T2 - A report from the children's oncology group

AU - Pollack, Ian F.

AU - Hamilton, Ronald L.

AU - Sobol, Robert W.

AU - Nikiforova, Marina N.

AU - Nikiforov, Yuri E.

AU - Lyons-Weiler, Maureen A.

AU - LaFramboise, William A.

AU - Burger, Peter C.

AU - Brat, Daniel J.

AU - Rosenblum, Marc K.

AU - Gilles, Floyd H.

AU - Yates, Allan J.

AU - Zhou, Tianni

AU - Cohen, Kenneth J

AU - Finlay, Jonathan L.

AU - Jakacki, Regina I.

PY - 2010/12

Y1 - 2010/12

N2 - Background: Alkylating agents are commonly used in the treatment of childhood malignant gliomas. Overexpression of O6-methylguanine-DNA methyltransferase (MGMT) constitutes an important mechanism for resistance to such agents, and MGMT status has been associated with outcome in several recent trials. Deficiency in mismatch repair (MMR) function has been implicated in preclinical studies as an additional potential mechanism of resistance to methylating agents, such as temozolomide, independent of tumor MGMT status. However, the frequency of this abnormality as a clinical resistance mechanism in childhood malignant gliomas has not been well characterized. Methods: To address this issue, we examined the frequency of microsatellite instability (MSI), a marker of defective MMR, in a series of 68 tumors, derived from newly diagnosed patients treated on the Children's Cancer Group 945 study, and the Children's Oncology Group ACNS0126 and 0423 studies. MSI was assessed using a panel of six microsatellite markers, including BAT-25, BAT-26, CAT-25, D2S123, D5S346, and D17S250. MGMT immunoreactivity was assessed in parallel to allow comparison of the relative incidence of MGMT overexpression and MSI. Results: Only three tumors had high-level MSI involving three or more markers; the remainder had no MSI at any of the loci examined. These children did not have unusual features in terms of their outcome. In contrast to the infrequency of MSI, 25 tumors (37%) exhibited MGMT overexpression as assessed by immunohistochemistry. None of the tumors with MSI exhibited overexpression of MGMT. Conclusion: MMR deficiency is an infrequent contributor to initial alkylator resistance in children with malignant gliomas.

AB - Background: Alkylating agents are commonly used in the treatment of childhood malignant gliomas. Overexpression of O6-methylguanine-DNA methyltransferase (MGMT) constitutes an important mechanism for resistance to such agents, and MGMT status has been associated with outcome in several recent trials. Deficiency in mismatch repair (MMR) function has been implicated in preclinical studies as an additional potential mechanism of resistance to methylating agents, such as temozolomide, independent of tumor MGMT status. However, the frequency of this abnormality as a clinical resistance mechanism in childhood malignant gliomas has not been well characterized. Methods: To address this issue, we examined the frequency of microsatellite instability (MSI), a marker of defective MMR, in a series of 68 tumors, derived from newly diagnosed patients treated on the Children's Cancer Group 945 study, and the Children's Oncology Group ACNS0126 and 0423 studies. MSI was assessed using a panel of six microsatellite markers, including BAT-25, BAT-26, CAT-25, D2S123, D5S346, and D17S250. MGMT immunoreactivity was assessed in parallel to allow comparison of the relative incidence of MGMT overexpression and MSI. Results: Only three tumors had high-level MSI involving three or more markers; the remainder had no MSI at any of the loci examined. These children did not have unusual features in terms of their outcome. In contrast to the infrequency of MSI, 25 tumors (37%) exhibited MGMT overexpression as assessed by immunohistochemistry. None of the tumors with MSI exhibited overexpression of MGMT. Conclusion: MMR deficiency is an infrequent contributor to initial alkylator resistance in children with malignant gliomas.

KW - Anaplastic glioma

KW - Childhood

KW - Glioblastoma

KW - MGMT

KW - Microsatellite instability

KW - Mismatch repair

KW - Treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=77958579289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958579289&partnerID=8YFLogxK

U2 - 10.1002/pbc.22634

DO - 10.1002/pbc.22634

M3 - Article

C2 - 20589656

AN - SCOPUS:77958579289

VL - 55

SP - 1066

EP - 1071

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -